The Swiss company said it will use the funding to accelerate commercialization of its blood-based calcification propensity test for kidney disease patients.
The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.
Ethos said Agena's MALDI-TOF-based MassArray system will allow for more rapid and lower-cost detection of SARS-Cov-2 variants than next-generation sequencing.
The company said it expects revenue growth to be approximately 57 percent year over year and non-GAAP core revenue growth to be approximately 29 percent.
The firm said its rapid antigen test provided 97.3 percent sensitivity and 99.6 percent specificity in clinical studies, and it is developing a saliva-based version.
This modular system uses a high-throughput version of the company's Applied Biosystems TaqPath COVID-19 Combo Kit, which received an EUA in March 2020.
The test, which runs on Ortho's Vitros system, was first CE marked in October for use with nasopharyngeal swab specimens and certain viral transport media.
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years.
Hologic intends to invest in assay development for Mobidiag's Novodiag PCR platform, which provides high-level multiplexing to detect infectious disease organisms.
CA Healthcare Acquisition, a special purpose acquisition company, said the transaction will support the development of LumiraDx’s pipeline of more than 30 assays.
The company's test uses self-collected saliva samples from potential parents to assess their future child's genetic predisposition to various diseases.
